Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Earnings for Adicet Bio, Inc. (ACET)
Earnings in 2023 (TTM): $-142,658,000
According to Adicet Bio, Inc.'s latest financial reports the company's current earnings (TTM) are $-142,658,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Adicet Bio, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-142,658,000 | $-142,658,000 |
| 2022 | $-69,790,000 | $-67,029,000 |
| 2021 | $-62,124,000 | $-61,999,000 |
| 2020 | $-39,493,000 | $-36,678,000 |
| 2019 | $-28,119,000 | $-28,138,000 |
| 2018 | $-9,888,000 | $-9,299,000 |
| 2017 | $-33,778,000 | $-33,778,000 |
| 2016 | $-1,000 | $-1,000 |
| 2015 | $44.67 M | $29 M |
| 2014 | $34.55 M | $22.33 M |
| 2013 | $34.55 M | $22.33 M |
| 2012 | $24.74 M | $16.98 M |
| 2011 | $16.96 M | $8.97 M |
| 2010 | $10.2 M | $6.58 M |
| 2009 | $12.73 M | $8.63 M |
| 2008 | $22.19 M | $13.47 M |